198 related articles for article (PubMed ID: 25151742)
21. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.
Zhang XQ; Wang ZW; Fan JW; Li YP; Jiao Z; Gao JW; Peng ZH; Liu GL
Ther Drug Monit; 2012 Apr; 34(2):126-33. PubMed ID: 22377746
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
23. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction.
Oteo I; Lukas JC; Leal N; Suarez E; Valdivieso A; Gastaca M; Ortiz de Urbina J; Calvo R
Eur J Clin Pharmacol; 2013 Jan; 69(1):65-74. PubMed ID: 22660442
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data.
Vucićević K; Miljković B; Velicković R; Pokrajac M; Mrhar A; Grabnar I
Ther Drug Monit; 2007 Dec; 29(6):781-8. PubMed ID: 18043476
[TBL] [Abstract][Full Text] [Related]
25. Limited sampling strategies for monitoring tacrolimus in pediatric liver transplant recipients.
Delaloye JR; Kassir N; Lapeyraque AL; Alvarez F; Lallier M; Beaunoyer M; Labbé L; Théorêt Y; Litalien C
Ther Drug Monit; 2011 Aug; 33(4):380-6. PubMed ID: 21743386
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the nonparametric estimation method in NONMEM VI.
Savic RM; Kjellsson MC; Karlsson MO
Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.
Chen YS; Liu ZQ; Chen R; Wang L; Huang L; Zhu X; Zhou TY; Lu W; Ma P
Acta Pharmacol Sin; 2017 Aug; 38(8):1195-1204. PubMed ID: 28552913
[TBL] [Abstract][Full Text] [Related]
28. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic parameter estimation: population size versus number of samples.
Girgis S; Pai SM; Girgis IG; Batra VK
AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
[TBL] [Abstract][Full Text] [Related]
31. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
32. Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life.
Choi S; Jeon S; Yim DS; Han S
Drug Des Devel Ther; 2020; 14():811-821. PubMed ID: 32158198
[TBL] [Abstract][Full Text] [Related]
33. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
35. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
Langers P; Press RR; den Hartigh J; Cremers SC; Baranski AG; Lamers CB; Hommes DW; van Hoek B
Ther Drug Monit; 2008 Aug; 30(4):456-61. PubMed ID: 18641539
[TBL] [Abstract][Full Text] [Related]
36. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
Tod M; Aouimer A; Petitjean O
Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations.
Liao M; Wang M; Zhu X; Zhao L; Zhao M
Ther Drug Monit; 2022 Oct; 44(5):615-624. PubMed ID: 36101928
[TBL] [Abstract][Full Text] [Related]
39. Failure of traditional trough levels to predict tacrolimus concentrations.
Macchi-Andanson M; Charpiat B; Jelliffe RW; Ducerf C; Fourcade N; Baulieux J
Ther Drug Monit; 2001 Apr; 23(2):129-33. PubMed ID: 11294512
[TBL] [Abstract][Full Text] [Related]
40. A reduction in between subject variability is not mandatory for selecting a new covariate.
Lagishetty CV; Vajjah P; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
